Entera Bio Ltd.
NASDAQ:ENTXBiotechnology
+$0.00 today
- Market cap
- $567.69M
- Beta
- 1.49
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.26
Volume 0.49M
Average 0.16M
ENTX Total Non-current Liabilities
All obligations due after more than one year.
Entera Bio Ltd.NASDAQ: ENTX
Total Non-current Liabilities · Q1 FY2026 · quarter ended Mar 2026
Total non-current liabilities rises 44.8% from a year ago
Total non-current liabilities stood at $866K at the end of Q1 FY2026, up 44.8% from a year earlier and up 25.7% from the prior quarter. Over 3 fiscal years it compounded at +178.2% a year.
Context
- Total non-current liabilities amounted to 6.6% of total assets at the end of Q1 FY2026, up 3.8 pp from a year earlier.
- Total non-current liabilities increased in 2 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether total non-current liabilities keeps rising in the next quarterly balance sheet after a +44.8% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Total Non-current Liabilities history
USD · from the balance sheet
- Latest · FY2025
- 689K USD
- Year-over-year change
- +414.2%
- 4-year CAGR
- +27.5%
| Period | Period end | Total Non-current Liabilities | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 689K | +414.2% |
| FY2024 | 2024-12-31 | 134K | -53.5% |
| FY2023 | 2023-12-31 | 288K | +800.0% |
| FY2022 | 2022-12-31 | 32K | -87.7% |
| FY2021 | 2021-12-31 | 261K | — |
Total Non-current Liabilities vs competitors
How ENTX compares with its peers on the latest reported figures
- ENTX's Mar 2026 total non-current liabilities of $866K is the 7th highest of the 10 companies compared; the peer median is $16.92M.
- Its year-over-year change of +44.8% is the 2nd highest of 9, against a peer median of -28.7%.
- Total non-current liabilities amounts to 6.6% of total assets for ENTX, versus a peer median of 11.6%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Mar 2026 | $165.2M | -47.4% | -13.5% | 88.6% | |
IRDOpus Genetics, Inc. | Mar 2026 | $103.28M | +448.1% | — | 154.6% |
| Mar 2026 | $71.78M | -12.9% | -33.4% | 61.0% | |
| Mar 2026 | $20.41M | -11.5% | -9.4% | 7.5% | |
| Mar 2026 | $16.92M | -42.9% | — | 12.7% | |
| Mar 2026 | $5.79M | -33.5% | -39.3% | 11.6% | |
| Mar 2026 | $866K | +44.8% | +178.2% | 6.6% | |
| Mar 2026 | $598K | -95.9% | -66.4% | 1.0% | |
| Mar 2026 | $447.99K | — | +189.2% | 1.5% | |
| Apr 2026 | $140K | -23.9% | -2.3% | 0.9% | |
| Peer median (excluding ENTX) | $16.92M | -28.7% | -13.5% | 11.6% | |
Competitors are the stored peer set for ENTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Entera Bio Ltd.
NASDAQ:ENTX
Intrinsic Alpha fair value
Locked
Current Price
$3.26
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.